Overview

Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The primary objectives of this study is to compare the efficacy of paclitaxel monotherapy with irinotecan monotherapy as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress following first line therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Korean Cancer Study Group

Collaborator:

Boryung Pharmaceutical Co., Ltd

Treatments:

Albumin-Bound Paclitaxel
Camptothecin
Irinotecan
Paclitaxel